IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Quantitative analysis updated February 24, 2026. Data-driven, not AI-generated.
Based on our 6-factor quantitative model, Repare Therapeutics Inc. receives a Hold rating with a composite score of 64/100, ranking #360 out of 7,333 stocks in our coverage universe.
The stock scores particularly well on Momentum (83th percentile). However, its weakest factor is Investment at just the 36th percentile, which investors should monitor.
On a valuation basis, RPTX trades at a 74% discount to its sector median P/E, suggesting the market may be underpricing the company's earnings power.
Our composite score is built from six academically-proven factors, each measured as a percentile rank across our entire coverage universe of 7,333 stocks. Higher percentile scores indicate stronger relative performance on that dimension.
Repare Therapeutics Inc. shows solid profitability metrics that exceed the market median. Margins and returns on capital are healthy, suggesting a well-managed business with reasonable competitive positioning.
ROE: -49.8% · Gross Margin: 100.0% · Op. Margin: 9.7% · Net Margin: 28.0%
Repare Therapeutics Inc. appears reasonably priced relative to its fundamentals. Valuation multiples are below the sector median, offering a modest margin of safety for long-term investors.
P/E: 5.8 · P/B: 0.7 · P/S: 1.6 · EV/EBITDA: 24.5
Repare Therapeutics Inc. exhibits strong positive price momentum across multiple timeframes. The stock has been consistently outperforming the market, and momentum research (Jegadeesh & Titman, 1993) suggests this trend has a tendency to persist.
Momentum percentile rank indicates price trend strength across 3, 6, and 12 month horizons.
Repare Therapeutics Inc. is investing aggressively with high asset growth rates. While this may fuel future revenue expansion, academic evidence suggests that rapid investment intensity is often associated with lower subsequent returns.
D/E: 0.0%
Repare Therapeutics Inc. shows below-average volatility relative to the market. The stock's return profile is relatively stable, offering a smoother ride for risk-conscious investors.
Volatility and return consistency measured over trailing 12 months.
Repare Therapeutics Inc. has short interest levels near the market median. The amount of shares sold short is not unusual and does not represent a significant signal in either direction.
Short interest as a percentage of float, relative to the market universe.
Repare Therapeutics Inc. appears undervalued relative to its sector, trading at a 74% discount to the sector median P/E of 22.3x. This discount may represent an attractive entry point for value-oriented investors, though further analysis of growth expectations is warranted.
| Metric | RPTX | Manufacturing Median | vs. Sector |
|---|---|---|---|
| P/E Ratio | 5.8x | 22.3x | -74% |
| P/B Ratio | 0.7x | 2.6x | -75% |
| P/S Ratio | 1.6x | 2.4x | -33% |
| EV/EBITDA | 24.5x | 11.5x | +114% |
This stock exhibits below-average risk characteristics including low volatility, manageable debt, and stable return patterns. It may serve as a defensive holding in a diversified portfolio.
We'll email you when stocks you follow change their composite rating.
Comprehensive fundamental data for Repare Therapeutics Inc. compared against Manufacturing sector medians. All data sourced from SEC filings and updated daily.
| Metric | RPTX | Manufacturing Median |
|---|---|---|
| Market Cap | $76M | -- |
| P/E Ratio | 5.8x | 22.3x |
| P/B Ratio | 0.7x | 2.6x |
| P/S Ratio | 1.6x | 2.4x |
| EV/EBITDA | 24.5x | 11.5x |
| Return on Equity | -49.8% | -2.5% |
| Return on Assets | 2.0% | -0.1% |
| Gross Margin | 100.0% | 42.5% |
| Operating Margin | 9.7% | 1.3% |
| Net Margin | 28.0% | -0.2% |
| Revenue Growth | N/A | 5.9% |
| Debt / Equity | 0.0% | 0.2% |
| Dividend Yield | 0.0% | 0.0% |
| Beta | N/A | -- |
Repare Therapeutics Inc. currently receives a Hold rating, reflecting a balanced risk-reward profile. While the stock does not exhibit the strong multi-factor characteristics of our top-rated names, it also lacks the red flags that would warrant a more cautious stance. Existing shareholders may wish to maintain their positions while monitoring for improvements in the weaker factor scores. New investors may find better risk-adjusted opportunities elsewhere in the Manufacturing sector.
Disclaimer: This analysis is based on quantitative factor models and does not constitute personalized investment advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.